High TMB, GBD and PD-L1 Levels Linked to Better Response in Neoadjuvant Gem-iDRS or Cetrelimab Trial for Bladder Cancer
The SunRISe-4 trial evaluated neoadjuvant gemcitabine‑based immunotherapy with or without cetrelimab in patients with muscle‑invasive bladder cancer.
A biomarker sub‑analysis showed that patients with high baseline tumor mutational burden (TMB), genomic disease burden (GBD), and PD‑L1 expression were more likely to achieve a pathologic overall response.
These findings suggest that measuring TMB, GBD and PD‑L1 could help identify patients who will benefit most from this regimen, potentially guiding future trial designs and treatment decisions.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Genomic Disease Burden Markers, PD-L1 Expression Predictive of pOR With Neoadjuvant Gem-iDRS ± Cetrelimab in MIBC”
read at onclive ↗
comments(0)
5-min edit window · permanent after that